[go: up one dir, main page]

WO2011014863A3 - Prophylaxie contre les métastases cancéreuses - Google Patents

Prophylaxie contre les métastases cancéreuses Download PDF

Info

Publication number
WO2011014863A3
WO2011014863A3 PCT/US2010/044070 US2010044070W WO2011014863A3 WO 2011014863 A3 WO2011014863 A3 WO 2011014863A3 US 2010044070 W US2010044070 W US 2010044070W WO 2011014863 A3 WO2011014863 A3 WO 2011014863A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer metastasis
against cancer
prophylaxis against
prophylaxis
lcn2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/044070
Other languages
English (en)
Other versions
WO2011014863A2 (fr
Inventor
Eckhard U. Alt
Ralph B. Arlinghaus
Michael E. Coleman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE112010003137T priority Critical patent/DE112010003137T5/de
Priority to US13/387,852 priority patent/US20120219561A1/en
Publication of WO2011014863A2 publication Critical patent/WO2011014863A2/fr
Publication of WO2011014863A3 publication Critical patent/WO2011014863A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés prophylactiques destinés à réduire les métastases cancéreuses en ciblant les LCN2, MMP9, et CXCR4.
PCT/US2010/044070 2009-07-31 2010-08-02 Prophylaxie contre les métastases cancéreuses Ceased WO2011014863A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE112010003137T DE112010003137T5 (de) 2009-07-31 2010-08-02 Prophylaxe gegen krebsmetastasierung
US13/387,852 US20120219561A1 (en) 2009-07-31 2010-08-02 Prophylaxis Against Cancer Metastasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23043909P 2009-07-31 2009-07-31
US61/230,439 2009-07-31

Publications (2)

Publication Number Publication Date
WO2011014863A2 WO2011014863A2 (fr) 2011-02-03
WO2011014863A3 true WO2011014863A3 (fr) 2011-06-23

Family

ID=43529975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044070 Ceased WO2011014863A2 (fr) 2009-07-31 2010-08-02 Prophylaxie contre les métastases cancéreuses

Country Status (3)

Country Link
US (1) US20120219561A1 (fr)
DE (1) DE112010003137T5 (fr)
WO (1) WO2011014863A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080274104A1 (en) * 2005-02-10 2008-11-06 Arlinghaus Ralph B Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics
HUE029958T2 (en) 2005-12-13 2017-04-28 Exthera Medical Corp A method for removing extracellular microbes, inflammatory cells or inflammatory proteins from the body
JP5925693B2 (ja) 2009-12-01 2016-05-25 エクステラ・メディカル・コーポレーション 表面固定した多糖類を用いた、血液からのサイトカイン除去法
WO2013153138A1 (fr) * 2012-04-11 2013-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Aptamère de métalloprotéinase matricielle 9 (mmp-9) et ses utilisations
DK2861273T3 (da) * 2012-06-13 2017-11-27 Exthera Medical Corp Anvendelse af heparin og kulhydrater til behandling af cancer.
KR20170020749A (ko) 2014-04-24 2017-02-24 엑스테라 메디컬 코퍼레이션 고유속을 이용한 혈액으로부터 세균의 제거방법
JP7100454B2 (ja) 2014-09-22 2022-07-13 エクスセラ メディカル コーポレイション 装着型血液潅流デバイス
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
KR20220009400A (ko) 2019-05-16 2022-01-24 엑스테라 메디컬 코퍼레이션 내피 글리코칼릭스 구조의 조절 방법
WO2021137254A1 (fr) * 2020-01-03 2021-07-08 Advanced Centre For Treatment Research And Education In Cancer, Tata Memorial Centre Anticorps contre la lipocaline-2 et leurs utilisations
WO2022101906A1 (fr) * 2020-11-15 2022-05-19 Ramot At Tel Aviv University Ltd. Procédé et composition pharmaceutique pour inhiber la métastase cancéreuse

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20030195461A1 (en) * 1994-12-12 2003-10-16 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US20040132642A1 (en) * 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195461A1 (en) * 1994-12-12 2003-10-16 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US20030109690A1 (en) * 1999-09-29 2003-06-12 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20040132642A1 (en) * 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANJA MUELLER ET AL.: "Involvement of chemokine receptors in breast cancer metastasis.", NATURE, vol. 410, no. 6824, 2001, pages 50 - 56, XP002292390, DOI: doi:10.1038/35065016 *
HAN SHI ET AL.: "Lipocalin 2 promotes lung metastasis of murine breast cancer cells.", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 27, 2008, pages 83, XP021052958, Retrieved from the Internet <URL:http://www.jeccr.com/content/27/1/83> DOI: doi:10.1186/1756-9966-27-83 *

Also Published As

Publication number Publication date
DE112010003137T5 (de) 2012-06-06
US20120219561A1 (en) 2012-08-30
WO2011014863A2 (fr) 2011-02-03

Similar Documents

Publication Publication Date Title
WO2011014863A3 (fr) Prophylaxie contre les métastases cancéreuses
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
WO2011142858A3 (fr) Variants de la chlorotoxine, conjugués, et leurs méthodes d&#39;utilisation
WO2013046060A9 (fr) Papier et procédés de fabrication du papier
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2009126350A3 (fr) Procédés et compositions pour cibler la polyubiquitine
WO2011020114A3 (fr) Procédés de traitement du cancer par endopeptidases à reciblage de tachykinine
BRPI1006897A2 (pt) compostos, composições e métodos de prevenção da metástase de células cancerosas.
TW201129938A (en) Personal mapping system
WO2012103393A3 (fr) Lutte contre les cochenilles
CA121621S (en) Bottle
WO2011020115A3 (fr) Procédés de traitement du cancer par endopeptidases à reciblage de facteur de croissance
WO2011133504A3 (fr) Nanozymes, procédés de production de nanozymes, et procédés d&#39;utilisation de nanozymes
WO2011072099A3 (fr) Compositions et procédés comprenant des variants de protéase
WO2011016840A3 (fr) Procédés et compositions de traitement de troubles de répétition tri-nucléotidique
WO2011028807A3 (fr) Systèmes et procédés de métrologie
EP2480847A4 (fr) Traitement d&#39;hydrocarbure gazeux
WO2012006538A8 (fr) N-éthyl-n-phényl-1,2-dihydro-4-hydroxy-5-chloro-1-méthyl-2-oxoquinoléine-3-carboxamide deutéré, sels de ce composé et utilisations correspondantes
WO2010003057A3 (fr) Traitement du cancer
WO2011006002A3 (fr) Nanostructures recouvertes de métal et procédés associés
EP2504938A4 (fr) Procédés, systèmes et dispositifs permettant de fournir une interconnexion à l&#39;aide de fibre optique jusqu&#39;au bureau de l&#39;utilisateur
WO2009155502A3 (fr) Procédés informatiques, support lisible par ordinateur et systèmes pour déterminer une ou plusieurs caractéristiques d&#39;une plaquette
EP2472770A4 (fr) Procédé d authentification bidirectionnelle d entité avec introduction d une tierce partie en ligne
CA138917S (en) Beverage package
WO2011005554A3 (fr) Bactéries éthanologènes recombinantes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10805162

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1120100031371

Country of ref document: DE

Ref document number: 112010003137

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 13387852

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10805162

Country of ref document: EP

Kind code of ref document: A2